| Active substance | Enzalutamide |
| Holder | Astellas Pharma |
| Status | Closed |
| Indication | Asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer in adult patients whose disease progressed during or after androgen deprivation therapy (ADT) but for whom chemotherapy is not yet clinically indicated |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 11/04/2016 |
Xtandi®
Last updated on 13/09/2024